To Whom It May Concern:
As a practicing provider with a major interest in liver disease, I am writing on behalf of my patient to request that _____ approve coverage of AFP-L3 and DCP serum biomarkers used for risk assessment for the development of hepatocellular carcinoma (HCC).
My patient has advanced fibrosis or cirrhosis of the liver and is at a high risk of developing HCC. This patient is under a liver surveillance program which can enable earlier detection of liver cancer. If unchecked or detected when only palliative options are left, HCC is ultimately lethal. Currently, liver cancer is the #2 cause of cancer death worldwide, and at this point in time HCC is among the fastest growing causes of cancer death in the United States and has a 5 year survival rate of approximately 15% due to late diagnosis is most patients »»»